ArticleFrontiers in molecular biosciences2026
Plasma untargeted metabolomics reveals metabolic signatures associated with epilepsy and anti-seizure medication responsiveness.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy is a neurological disorder with heterogeneous anti-seizure medication responses and a lack of peripheral biomarkers for diagnosis and drug resistance assessment. This study aims to explore metabolic alterations and candidate metabolite panels associated with epilepsy and anti-seizure medication responsiveness. Methods: Untargeted metabolomic analysis was performed on plasma samples from 42 patients with epilepsy (PWE), including 20 patients with drug-resistant epilepsy (DRE) and 22 patients with drug-sensitive epilepsy (DSE), as well as 20 healthy controls (HCs). Multivariate and univariate statistical analyses, pathway analysis, machine-learning-based feature selection, and logistic regression modeling were conducted, with internal validation by bootstrap resampling. Transcriptomic data were analyzed and intersected with metabolomic findings at the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway level, followed by construction of a gene-metabolite-pathway network. Results: Between the PWE and HC groups, 3,329 significantly different features were identified. KEGG enrichment analysis showed that the differential metabolites were mainly enriched in the cyclic adenosine monophosphate signaling pathway, hypoxia-inducible factor-1 signaling pathway, and dopaminergic synapse pathway, and these three pathways were also enriched in the transcriptomic dataset. Three key candidate metabolites-palmitoylcarnitine, C18 (plasm)-18:1 PC, and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine-effectively discriminated PWE from HCs. Between the DRE and DSE groups, 1,074 differential ion features were identified. Six key candidate metabolites-L-kynurenine, indolelactate, glycodeoxycholic acid, N-acetylcytidine, citric acid, and 5-hydroxyindoleacetate-showed exploratory discriminatory ability between the DRE and DSE groups. Conclusion: This study revealed plasma metabolic signatures associated with epilepsy and anti-seizure medication responsiveness. The identified candidate metabolites and pathways provide preliminary metabolic evidence that requires further validation in independent cohorts and mechanistic studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.